SRA-36
SRA-36 is a CLC-K chloride channel inhibitor with selectivity over CLC-5 and CLC-1 chloride channels. SRA-36 blocks CLC-Ka currents with an IC50 of 6.6 μM and a Kd of 3.8 μM. SRA-36 blocks chloride currents mediated by targeted channels, and inhibits currents from hypertension-associated CLC-KaA447T and CLC-KaY315F polymorphisms. SRA-36 can be used for the research of hypertension.
For research use only. We do not sell to patients.
- Formula: C22H16O3
- Molecular Weight:328.36
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
SRA-36 potently inhibits chloride currents from wild-type CLC-Ka channels heterologously expressed in HEK293 cells, with an IC50 of 6.6 μM[1].
SRA-36 potently inhibits chloride currents from wild-type CLC-Ka channels heterologously expressed in MDCK cells, with an apparent KD of 3.8 μM[1].
SRA-36 potently inhibits chloride currents from CLC-Kb and rat CLC-K1 channels heterologously expressed in HEK293 cells, reducing currents by ~90% at 50 μM[1].
SRA-36 (5 μM) does not inhibit chloride currents from CLC-5 or CLC-1 channels heterologously expressed in HEK293 cells at a concentration of 5 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 328.36
-
Formula C22H16O3
-
SMILES
OC(C1=C(C2=CC(CC3=CC=CC=C3)=CC=C2O1)C4=CC=CC=C4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)